“Dr. Wainberg’s passing is a tremendous loss for the scientific community,” said IAVI President and CEO Mark Feinberg. “His extraordinary contributions to the field of HIV research and development continue to be an inspiration to me and to all who knew him. Discoveries stemming from his investigations and collaborations have significantly advanced treatment, prevention and cure research."
Among these contributions was the identification of several mutations in the HIV genome that are responsible for drug resistance. In recent years, he also turned his attention to researching a potential HIV cure based on the possibility that HIV may be unable to form resistance to compounds called integrase inhibitors that block viral replication.
Eric Goosby, Chair of IAVI's Board of Directors and UN Special Envoy on Tuberculosis, also remembered Wainberg. "Mark was an unusually personable member of the global research community, one whose informality masked the magnitude of his scientific accomplishments,” Goosby said. “He was one of a very small number of basic research scientists to become so actively involved in the political, social, and personal dimensions of the epidemic, a level of commitment that, in turn, sharpened his scientific insight.”
His commitment to the worldwide AIDS response extended beyond science into advocacy, with a direct impact on IAVI. In 2003 Wainberg joined a group of multi-sector experts on IAVI’s inaugural Policy Advisory Committee to guide the organization’s linked activities in both global advocacy and policy research. This followed his influential term as President of the International AIDS Society (1998-2000), which helped catalyze expanded HIV treatment access for developing countries.
Wainberg, 71, was the head of AIDS research at the Lady Davis Institute for Medical Research, director of the McGill University AIDS Center at the Montreal Jewish General Hospital, and professor of medicine, microbiology, and immunology at McGill University in Montreal, Canada.